INCOG’s CEO explains vision for the future of sterile injectable manufacturing

Founded in June 2020, INCOG has secured FDA-approval and now establishes itself as a new force in contract manufacturing with a focus on sterile injectables. 
As we gear up for CDMO Live, we had the opportunity to speak with Corey Lewis, CEO, President, and Founder of INCOG Biopharma Services, about their dedicated approach to serving customers in the high-growth sterile injectable market.
Despite the company only being four years old, INCOG’s leadership team brings decades of industry experience. Cory says he has brought the ‘band back together’ by reuniting seasoned professionals to create a tier-one contract manufacturing organisation (CDMO).
“Our goal is to compete at the highest level, and that requires a seasoned executive team with a robust investment strategy.”
INCOG’s investments in vial, syringe, and cartridge filling capabilities are “just the beginning” says Lewis. “We’re also expanding into quality control, lab stability services, and eventually, auto-injector device assembly and final packaging. Our long-term site master plan outlines our ambition to not only enhance  filling capacity, but also integrate additional business units to support commercial packaging and device assembly.”
Read the full interview